NCT06270225 - A Study of SSGJ-613 in Gout Subjects Initiating Urate-Lowering Treatment. | Biotech Hunter

Enrollment

157

Participants

Timeline

Start Date

March 30, 2024

Primary Completion Date

October 31, 2024

Study Completion Date

December 31, 2024

Conditions

Gout Arthritis

Interventions

DRUG

Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 100 mg

Subjects will receive one s.c. injection of SSGJ-613 on Day 1.

DRUG

Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 200 mg

Subjects will receive one s.c. injection of SSGJ-613 on Day 1.

DRUG

Colchicine 0.5 mg

Subjects will receive 0.5mg/d Colchicine for 12 weeks.

Trial Locations (1)

Shanghai Huashan Hospital Fudan University-Rheumatology, Shanghai

All Listed Sponsors

lead

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

INDUSTRY